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Down-regulation of lipoprotein lipase and VLDL receptor in proteinuria and hyperlipidemia first appear at 8 to 10
rats with focal glomerulosclerosis. weeks of age and steadily increase in intensity leading
Background. Patients and animals with nephrotic syndrome to severe nephrotic syndrome, marked hyperlipidemiaand those with chronic renal failure (CRF) often exhibit hyper-
and chronic renal insufficiency by 32 weeks of age in thetriglyceridemia and impaired very low-density lipoprotein
male animals [1]. These events are less severe and occur(VLDL) clearance. Imai rats that were originally derived from
Sprague-Dawley rats develop spontaneous proteinuria, hyper- at a later age (9 months of age) in female animals. The
lipidemia, progressive renal insufficiency and histologic changes protective effect of female gender is reversed by ovariec-
of focal glomerulosclerosis (FGS), closely resembling human tomy. However, orchiectomy does not modify the courseFGS. This study was undertaken to test the hypothesis that
of the disease in the male rats [2].elevation of plasma triglyceride and VLDL concentrations in
Imai hyperlipidemic rats were originally derived fromthe Imai rats is associated with deficiency of lipoprotein lipase
(LPL) and VLDL receptor which are the main pathways of the mating of a male Sprague-Dawley rat that exhibited
triglyceride-rich lipoprotein clearance. renal involvement and hyperlipidemia while consuming
Methods. Male Imai and Sprague-Dawley control rats were a low fat basal diet [2]. The histological and biochemicalfed regular rat chow and studied at 10 and 34 weeks of age.
features of renal disease in the Imai hyperlipidemic ratsTissue LPL and VLDL-r protein abundance (Western analysis)
bear considerable resemblance to idiopathic progressiveand post-heparin lipolytic activity were determined.
Results. At 10 weeks of age, Imai rats showed mild protein- focal glomerulosclerosis in humans [1, 3]. In a series of
uria, moderate hyperlipidemia, normal creatinine clearance and earlier studies, Liang and Vaziri demonstrated marked
blood pressure. By 34 weeks of age, the study animal exhibited down-regulations of skeletal muscle, myocardial and adi-
severe proteinuria, marked hyperlipidemia, significant renal in-
pose tissue lipoprotein lipase (LPL) and very low-dens-sufficiency and hypertension. This was associated with a severe
ity lipoprotein (VLDL) receptor (VLDL-r) in Sprague-progressive reduction in skeletal muscle and adipose tissue
LPL and VLDL-r protein abundance and depressed plasma Dawley rats with puromycin-induced nephrotic syndrome
post heparin, lipolytic activity. [4, 5]. They have further shown that rats with chronic re-
Conclusion. Progressive hyperlipidemia in the Imai rats with nal insufficiency induced by 5/6 nephrectomy exhibit dys-
spontaneous FGS is accompanied by severe combined LPL
lipidemia and severe acquired LPL and VLDL-r defi-and VLDL-r deficiencies that can, in part, account for the as-
ciencies [6–9]. Given the critical role of LPL and VLDL-rsociated hypertriglyceridemia and elevated plasma VLDL con-
centrations. in clearance of triglyceride-rich lipoproteins, their ac-
quired deficiency contributes to the pathogenesis of hy-
pertriglyceridemia and elevation of VLDL concentration
Imai hyperlipidemic rats exhibit a spontaneous glom- in these experimentally induced models of nephrotic syn-
erulopathy that is marked by progressive focal-segmental drome and renal insufficiency. The present study docu-
glomerulosclerosis (FGS), and heavy proteinuria leading ments severe down-regulation of LPL and VLDL-r in the
to chronic renal insufficiency. Onset of proteinuria is cou- Imai rats with spontaneous focal-segmental glomerulo-
pled with a progressive rise in plasma cholesterol and sclerosis (FGS), which closely resembles idiopathic FGS
triglyceride concentration in these animals. Discernible in humans and presents with severe hyperlipidemia heavy
proteinuria and renal insufficiency.
Key words: nephrotic syndrome, proteinuria, renal failure, hypertri-
glyceridemia, hyperlipidemia, lipoprotein lipase, very-low density lipo-
METHODSprotein-receptor.
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and bred in the animal facility of Saga Medical School Measurement of VLDL receptor protein abundance
(Saga, Japan). They were fed a regular rat chow (contain- Very low-density lipoprotein-receptor protein abun-
ing 24.8% protein, and 0.08% cholesterol) and housed dance in the skeletal muscle and adipose tissue was quan-
in a climate-controlled space with 12-hour day and night tified by Western blot analysis in a manner that was
cycles. A group of age-matched male Sprague-Dawley rats identical to that described by Vaziri and Liang previously
[8]. The antibody employed in this assay was derivedserved as controls. All animals were allowed free access
from hybridoma cell line, IgG-GAG, which produces ato food and water ad libitum. Six animals from each group
monoclonal antibody recognizing the cytoplasmic do-were monitored for thirty-four weeks. Another subgroup
main of VLDL-r in humans, rats and several other spe-of six hyperlipidemic and control rats were observed
cies. This antibody was prepared in our laboratory.for ten weeks. Arterial pressure was measured by a tail
plethysmograph (Harvard Apparatus MAS) as described Data analysis
in our earlier studies [10]. A 24-hour urine collection
Analysis of variance, the Duncan multiple range test,was obtained for determinations of urinary protein and
Student t test and regression analysis were used in statis-creatinine excretion using metabolic cages. At the con-
tical evaluation of the data as appropriate. P values less
clusion of each observation period, animals were anes- than 0.05 were considered significant. Data are given as
thetized with intraperitoneal injections of pentobarbital mean  SEM.
(50 mg/kg) and euthanized by exsanguination using car-
diac puncture. Soleus muscle and supratesticular fat pad
RESULTSwere harvested and snap frozen in liquid nitrogen imme-
General datadiately and stored at 70C until processed. In addition,
plasma was separated and used for measurements of Data are summarized in Table 1. At 10 weeks of age,
lipids, creatinine and albumin concentrations. the Imai rats exhibited a mild elevation of plasma total
cholesterol, and a modest increase in plasma triglyceride
Measurement of plasma post-heparin lipolytic activity and VLDL-triglyceride concentrations. This was accom-
panied by a normal plasma creatinine concentration andSubgroups of six animals in each group were used for
a mild increase in urinary protein excretion. With timedetermination of post-heparin lipolytic activity. Briefly,
plasma cholesterol, LDL cholesterol, VLDL cholesterol,after 24 hours of fasting, animals were injected with
triglyceride and VLDL triglyceride concentrations rose,heparin, 30 U/kg into the tail vein. Ten minutes after
leading to severe hyperlipidemia by 34 weeks of age inheparin injection, blood samples were drawn from the
the Imai group. The rise in plasma lipid levels in thetail artery using ice-chilled syringes. The samples were
Imai rats was coupled with the development of severethen centrifuged at 1500  g at 4C for 15 minutes.
nephrotic proteinuria, doubling of serum creatinine, aPlasma was then separated and stored at 70C until
50% decline in creatinine clearance and a steady rise in
processed. LPL enzymatic activity in the plasma samples blood pressure.
was measured using the F-LPL kit purchased from Dai-
nabbot, Inc. (Tokyo, Japan). LPL data
The Imai rats showed a moderate reduction in adipose
Routine biochemical determinations tissue LPL protein abundance (53% of control) at 10
Serum total cholesterol, triglyceride, creatinine and al- weeks of age (Fig. 1). Adipose tissue LPL protein abun-
bumin concentrations were measured by a synchro CX3 dance further declined to about 27% of the control value
by 34 weeks of age (Fig. 1). The reduction in adiposeautoanalyzer (Beckman Instruments, Inc., Fullerton, CA,
tissue LPL in the Imai rats was accompanied by an evenUSA). Urinary protein concentration was determined
more severe reduction of skeletal muscle LPL proteinby a kit purchased from Wako Pure Chemical Industries
abundance, approximating less than 11% of that found(Tokyo, Japan).
in the control group at 10 weeks of age. Skeletal muscleCreatinine clearance was calculated from urinary and
LPL abundance was equally low in the Imai rats studiedplasma creatinine values using the standard formula.
at 34 weeks of age (Fig. 2). The reduction in skeletal
muscle and adipose tissue immunodetectable LPL abun-Measurement of tissue immunodetectable
dance in the Imai rats was accompanied by a progres-LPL abundance
sive reduction in the plasma post-heparin LPL activity
Lipoprotein lipase protein abundance in the adipose (Fig. 3).
tissue and skeletal muscle was determined by Western
VLDL receptor datablot analysis as described previously by Vaziri, Wang
and Liang [7]. The antibody employed in this assay was Adipose tissue VDLD-r protein abundance was se-
generously supplied by Professor John Brunzell (Uni- verely depressed in the Imai rats at 10 weeks of age
(29% of the control value) and declined further (to ap-versity of Washington, Seattle, WA, USA).
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Table 1. Serum concentrations of total cholesterol, LDL-Chol, VLDL-Chol, total triglycerides, VLDL-TG, albumin and creatinine,
creatinine clearance (CCr), urinary protein excretion and systolic blood pressure in normal control (CTL),
10-week-old FGS and 34-week-old FGS rats
CTL FGS 10 weeks FGS 34 weeks P
(N6) (N6) (N6) (ANOVA)
Cholesterol mg/dL 63.72.9 74.01.4a 357.019.6a,b 0.0001
LDL-Chol mg/dL 12.33.0 14.63.5 189.412.5a,b 0.0001
VLDL-Chol mg/dL 23.41.5 29.65.1 77.711.2a,b 0.0005
Triglyceride mg/dL 73.110.2 107.214.4a 218.115.2a,b 0.005
VLDL-TG mg/dL 63.010.2 98.99.2a 194.416.3a,b 0.0005
Albumin g/dL 3.700.1 3.500.1 2.800.1a,b 0.0005
Creatinine mg/dL 0.540.29 0.430.01a 1.050.14a,b 0.0001
CCr ml/min/g kw 0.540.03 0.490.03 0.200.04a,b 0.0001
Urinary protein mg/24 h 35.25.5 10313.6a 467.027.7a,b 0.0001
Blood pressure mm Hg 116.75.9 133.68.6a 187.512.6a,b 0.001
Values are means  SEM. Abbreviation is kw, kidney weight.
a P  0.05 vs. CTL
b P  0.05 vs FGS 10 weeks
Fig. 2. Representative Western blot and group data depicting skeletalFig. 1. Representative Western blot and group data depicting adipose
muscle LPL protein abundance in the normal control (CTL) group andtissue lipoprotein lipase (LPL) protein abundance in the normal control
Imai rats with spontaneous focal glomerulosclerosis studied at ages 10(CTL) group and Imai rats with spontaneous focal glomerulosclerosis
weeks (FSG10) and 34 weeks (FSG34). N  6 rats in each group, *P studied at ages 10 weeks (FSG10) and 34 weeks (FSG34). N  6 rats in 0.01 versus other groups.each group, *P  0.01 versus other groups.
proximately 19% of the control) by 34 weeks of age (Fig. 0.83, P  0.01) and skeletal muscle LPL abundance
4). Similarly, skeletal muscle VLDL-r protein abundance (r  0.76, P  0.01). Similarly, plasma triglyceride
was severely reduced to about 10% of the control value
concentration showed an inverse correlation with adi-in these animals at 10 weeks of age. Skeletal muscle
pose tissue VLDL-r (r  0. 77, P  0.05) and skeletalVLDL-r levels were equally low in animals studied at
muscle VLDL-r abundance (r0.73, P 0.05; Fig. 6).34 weeks of age (Fig. 5).
Plasma post-heparin LPL enzymatic activity was directly
Correlations related to adipose tissue LPL protein abundance (r 
0. 81, P 0.01) and skeletal muscle LPL abundance (rPlasma triglyceride concentration was inversely re-
lated to adipose tissue LPL protein abundance (r  0.8, P  0.01).
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Fig. 3. Plasma post-heparin LPL activity in the normal control (CTL)
group and Imai rats with spontaneous focal glomerulosclerosis studied
at ages 10 weeks (FSG10) and 34 weeks (FSG 34). N  6 in each group,
*P  0.01 versus other groups.
Fig. 4. Representative Western blot and group data depicting adipose
tissue VLDL-r protein abundance in the normal control (CTL) group
and Imai rats with spontaneous focal glomerulosclerosis studied at agesDISCUSSION
10 weeks (FSG10) and 34 weeks (FSG34). N  6 rats in each group,
Lipoprotein lipase is a member of the lipase gene *P  0.01 versus other groups.
family, which includes pancreatic and hepatic lipase iso-
types. LPL is expressed in several different tissues, espe-
cially fat, skeletal muscle and mycardium. LPL produced
dance paralleling the steady rise in plasma lipid concentra-by these cells is secreted into the corresponding capillary
tions. The reduction in LPL protein abundance was cou-networks wherein it binds to heparan sulfate proteogly-
pled with a significant reduction in plasma post-heparincans expressed on the endothelial surface. LPL plays a
lipolytic activity. The latter finding provided functional
major role in peripheral metabolism of plasma triglycer-
evidence for the observed down-regulation of immuno-
ide-rich lipoproteins, namely VLDL and chylomicrons.
detectable LPL in the study animals.
In the presence of apolipoprotein CII (Apo-CII), LPL Experimental nephrotic syndrome induced by puromy-
catalyzes hydrolysis of triglycerides contained in chylo- cin aminonucleoside in rats causes moderate reduction of
microns and VLDL particles leading to release of free LPL expression in skeletal muscle and adipose tissue that
fatty acids and generation of VLDL and chylomicron rem- contributes to the associated hyperlipidemia [4]. Likewise,
nants. Free fatty acids produced in this manner are taken hyperlipidemia in rats with experimental chronic renal fail-
up by myocytes and adipocytes for energy production ure induced by 5/6 nephrectomy is accompanied by and
and storage, respectively [11]. Inherited and acquired causally related to acquired down-regulation of LPL ex-
LPL deficiencies result in hypertriglyceridemia and im- pression [6, 7]. The magnitude of decline in tissue LPL
paired clearance of chylomicrons and VLDL particles. abundance observed in the Imai rats with spontaneous
Both nephrotic syndrome and chronic renal failure are FSG and a combination of heavy proteinuria and renal
associated with elevation of plasma triglyceride concen- insufficiency was far greater than that seen in animals
tration and impaired clearance of triglyceride-rich lipo- with either experimental chronic renal failure [6, 7] or
proteins [12–14]. These abnormalities are associated with puromycin-induced nephrotic syndrome [4]. It should be
and, in part, due to the LPL deficiency [4, 15, 16]. Devel- noted that proteinuria was minimal in our animals with
opment of proteinuria and hyperlipidemia in the 10-week- chronic renal failure produced by 5/6 nephrectomy [6, 7]
old Imai hyperlipidemic rats was accompanied by marked and glomerular filtration rate was normal in our animals
down-regulation of LPL abundance in skeletal muscle with puromycin-induced nephrotic syndrome [4]. In con-
and adipose tissue. Progression of proteinuria and devel- trast, by 34 weeks of age, the Imai rats with spontaneous
opment of renal insufficiency noted by 34 weeks of age FSG exhibited a combination of severe proteinuria and
moderate renal insufficiency that could have worked inwas accompanied by a further decline in tissue LPL abun-
Fig. 5. Representative Western blot and group data depicting skeletal
muscle VLDL-r protein abundance in the normal control (CTL) group
and Imai rats with spontaneous focal glomerulosclerosis studied at ages
10 weeks (FSG10) and 34 weeks (FSG34). N  6 rats in each group,
*P  0.01 vs. other groups.
concert to produce a more severe down-regulation of
LPL expression.
Very-low density lipoprotein-receptor is a novel mem-
ber of the LDL receptor family that binds and internal-
izes VLDL but not LDL particles. Tissue distribution of
VLDL-r is distinctly different from that of LDL receptor
and is identical to that of LPL. Accordingly, VLDL-r is
abundantly expressed in the heart, skeletal muscle and
adipose tissue, which use fatty acids for energy produc-
tion and storage, respectively [17–19]. Based on its bind-
ing specificity and tissue distribution, VLDL-r is thought
to play a role in metabolism of triglyceride-rich VLDL
particles. In fact, earlier studies by our group have re-
vealed marked down-regulations of skeletal muscle and
adipose tissue VLDL-r in rats with experimental chronic
renal failure, as well as those with puromycin-induced
nephrotic syndrome [5, 8, 9]. The Imai hyperlipidemic
rats employed here exhibited marked elevations of plasma
triglyceride and VLDL concentrations by 34 weeks of age.
This was accompanied by a severe reduction of skeletal
muscle and adipose tissue VLDL-r abundance. By lim-
iting VLDL clearance, the observed VLDL-r deficiency
could potentially contribute to the elevation of VLDL
Fig. 6. Correlations between plasma triglyceride concentration, fat andand triglyceride concentrations in these animals that muscle tissue LPL and VLDL-r proteins in the normal control group
showed a concomitant LPL deficiency. It is of note that (; N  6) and Imai rats with spontaneous focal glomerulosclerosis
(; N  9).in addition to their shared localization in the same tis-
sues, LPL and VLDL receptors appear to be functionally
interdependent. For instance, LPL has been shown to
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